SIC 2835 – In Vitro and In Vivo Diagnostic Substances
| Valuation | |
|---|---|
| Market Cap ($M) | 0.10 |
| Enterprise Value ($M) | 0.45 |
| Book Value ($M) | -2.56 |
| Book Value / Share | -0.09 |
| Price / Book | -0.04 |
| NCAV ($M) | -3.87 |
| NCAV / Share | -0.13 |
| Price / NCAV | -0.03 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -16.11 |
| Return on Assets (ROA) | -1.83 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.71 |
| Current Ratio | 0.76 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 4.18 |
| Assets | 5.49 |
| Liabilities | 8.05 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 9.18 |
| Operating Income | -16.28 |
| Net Income | -13.09 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Dilutive Effect Of Stock Options | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -12.11 |
| Cash from Investing | -0.04 |
| Cash from Financing | 11.06 |
(click for more detail) |
|
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| ATXI – Avenue Therapeutics, Inc. | AVRW – Avenir Wellness Solutions, Inc. |
| AVVH – AVVAA World Health Care Products, Inc. | AXIM – AXIM Biotechnologies, Inc. |
| AZNCF – AstraZeneca PLC |
Financial data and stock pages provided by
Fintel.io